The incidence and prognostic value of HER2 overexpression and cyclin D1 expression in patients with gastric or gastroesophageal junction adenocarcinoma in Israel

Oncology Letters

Volumn 5, Issue 2, 2013, Pages 559-563

  Bar Sela, Gil ^a   Hershkovitz, Dov ^b   Haim, Nissim ^a   Kaidar Person, Orit ^a   Shulman, Katerina ^a   Ben Izhak, Ofer ^b  

^a Division of Oncology   (Israel)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Cyclin D1; Gastric carcinoma; HER2; Israel; Survival

Indexed keywords

CAPECITABINE; CYCLIN D1; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUOROURACIL; TAXANE DERIVATIVE;

ADULT; AGED; ARTICLE; BIOPSY; CANCER MORTALITY; CANCER PROGNOSIS; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; ESOPHAGEAL ADENOCARCINOMA; FEMALE; GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; ISRAEL; MAJOR CLINICAL STUDY; MALE; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; SCORING SYSTEM; STOMACH ADENOCARCINOMA;

EID: 84871536503     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2012.1031     Document Type: Article

References (17)

1. Israel National Cancer Registry: Cancer Incidence Tables: Stomach. http://abush.health.gov.il/download/sartan/trends/Stomach.pdf. Accessed August 2009.
2. Slamon DJ, Godolphin W, Jones LA, et al: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science244: 707-712, 1989.
3. Scholl S, Beuzeboc P and Pouillart P: Targeting HER2 in other tumor types. Ann Oncol 12 Suppl 1: S81-87, 2001.
4. Chua TC and Merrett ND: Clinicopathologic factors associated with HER2-positive gastric cancer and its impact on survival outcomes-a systematic review. Int J Cancer 130: 2845-2856, 2012.
5. Tanner M, Hollmén M, Junttila TT, et al: Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol 16: 273-278, 2005.
6. Bang YJ, Van Cutsem E, Feyereislova A, et al: ToGA Trial Investigators: Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376: 687-697, 2010.
7. Weinberg RA: The retinoblastoma protein and cell cycle control. Cell 81: 323-330, 1995.
8. Yan B, Yau EX, Bte Omar SS, et al: A study of HER2 gene amplification and protein expression in gastric cancer. J Clin Pathol 63: 839-842, 2010.
9. Grabsch H, Sivakumar S, Gray S, Gabbert HE and Müller W: HER2 expression in gastric cancer: Rare, heterogeneous and of no prognostic value-conclusions from 924 cases of two independent series. Cell Oncol 32: 57-65, 2010.
10. Dreznik A, Purim O, Idelevich E, et al: Gastric cancer: biology and clinical manifestations in Israel. J Surg Oncol 105: 316-322, 2012.
11. Giuffrè G, Ieni A, Barresi V, Caruso RA and Tuccari G: HER2 status in unusual histological variants of gastric adenocarcinomas. J Clin Pathol 65: 237-241, 2012.
12. Hofmann M, Stoss O, Shi D, et al: Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology 52: 797-805, 2008.
13. Rüschoff J, Dietel M, Baretton G, et al: HER2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing. Virchows Arch 457: 299-307, 2010.
14. Rüschoff J, Hanna W, Bilous M, et al: HER2 testing in gastric cancer: a practical approach. Mod Pathol 25: 637-650, 2012.
15. Feakins RM, Nickols CD, Bidd H and Walton SJ: Abnormal expression of pRb, p16, and cyclin D1 in gastric adenocarcinoma and its lymph node metastases: relationship with pathological features and survival. Hum Pathol 34: 1276-1282, 2003.
16. Kishimoto I, Mitomi H, Ohkura Y, Kanazawa H, Fukui N and Watanabe M: Abnormal expression of p16(INK4a), cyclin D1, cyclin-dependent kinase 4 and retinoblastoma protein in gastric carcinomas. J Surg Oncol 98: 60-66, 2008.
17. Werner M, Chott A, Fabiano A and Battifora H: Effect of formalin tissue fixation and processing on immunohistochemistry. Am J Surg Pathol 24: 1016-1019, 2000.